MA53875A - Traitement avec des compositions d'igg hautement sialylées - Google Patents

Traitement avec des compositions d'igg hautement sialylées

Info

Publication number
MA53875A
MA53875A MA053875A MA53875A MA53875A MA 53875 A MA53875 A MA 53875A MA 053875 A MA053875 A MA 053875A MA 53875 A MA53875 A MA 53875A MA 53875 A MA53875 A MA 53875A
Authority
MA
Morocco
Prior art keywords
treatment
highly sialylated
igg compositions
sialylated igg
compositions
Prior art date
Application number
MA053875A
Other languages
English (en)
Inventor
Santiago Arroyo
William Denney
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MA53875A publication Critical patent/MA53875A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA053875A 2018-10-11 2019-10-11 Traitement avec des compositions d'igg hautement sialylées MA53875A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744536P 2018-10-11 2018-10-11
US201962879930P 2019-07-29 2019-07-29

Publications (1)

Publication Number Publication Date
MA53875A true MA53875A (fr) 2021-08-18

Family

ID=70164359

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053875A MA53875A (fr) 2018-10-11 2019-10-11 Traitement avec des compositions d'igg hautement sialylées

Country Status (11)

Country Link
US (2) US20210353752A1 (fr)
EP (2) EP4567428A3 (fr)
JP (2) JP2022502466A (fr)
KR (2) KR20210077706A (fr)
CN (1) CN113438953A (fr)
AU (2) AU2019357842A1 (fr)
BR (1) BR112021006852A2 (fr)
CA (1) CA3115821A1 (fr)
IL (1) IL282136A (fr)
MA (1) MA53875A (fr)
WO (1) WO2020077298A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018747A2 (fr) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoprotéines ayant des propriétés anti-inflammatoires
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
EP3058084A4 (fr) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
US20230192814A1 (en) * 2020-05-19 2023-06-22 Momenta Pharmaceuticals, Inc. Hyper-sialylated immunoglobulin
KR20230054395A (ko) * 2020-08-20 2023-04-24 모멘타 파머슈티컬스 인코포레이티드 시알릴화된 당단백질
WO2022038565A1 (fr) * 2020-08-21 2022-02-24 Janssen Biotech, Inc. Immunoglobuline hypersialylée
WO2024136368A1 (fr) * 2022-12-21 2024-06-27 건국대학교 산학협력단 UTILISATION D'IMMUNOGLOBULINE α-2,6-SIALYLÉE DANS LA PRÉVENTION OU LE TRAITEMENT DU SYNDROME DE L'ŒIL SEC OU DE MALADIES OCULAIRES INFLAMMATOIRES

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007235413B2 (en) * 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
ES2626080T3 (es) 2007-04-16 2017-07-21 Momenta Pharmaceuticals, Inc. Caracterización de N-glicanos utilizando exoglicosidasas
US9182467B2 (en) 2007-04-16 2015-11-10 Momenta Pharmaceuticals, Inc. Comparative analysis of protein conformations by using 2D NOESY NMR spectra
WO2008128216A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Méthodes de marquage de glycanes
WO2008128222A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Analyse de glycanes, glycopeptides ou glycoprotéines phosphorylés par imac
WO2008128230A1 (fr) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Produits de glycoprotéines de référence et procédés associés
CA2682744C (fr) 2007-04-16 2015-10-06 Momenta Pharmaceuticals, Inc. Methodes associees a la glycosylation de surface
US20110213137A1 (en) 2007-04-16 2011-09-01 Momenta Pharmaceuticals, Inc. Isotopically-labeled glycans
EP2135090A1 (fr) 2007-04-16 2009-12-23 Momenta Pharmaceuticals, Inc. Libération protéolytique de glycanes
AU2008240080A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
EP2135091B1 (fr) 2007-04-16 2011-06-08 Momenta Pharmaceuticals, Inc. Procédés faisant appel à la spectrométrie de masse pour évaluer des glycanes
US8216851B2 (en) 2007-04-16 2012-07-10 Momenta Pharmaceuticals, Inc. Characterization of N-glycan mixtures by nuclear magnetic resonance
EP2136896B1 (fr) 2007-04-16 2015-01-21 Momenta Pharmaceuticals, Inc. Procédés de chromatographie multidimensionnelle permettant de séparer des n-glycanes
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2010071817A2 (fr) 2008-12-19 2010-06-24 Momenta Pharmaceuticals, Inc. Caractérisation de glycanes à liaison o
US9103821B2 (en) 2008-12-19 2015-08-11 Momenta Pharmaceuticals, Inc. Methods related to modified glycans
JP2012515922A (ja) 2009-01-22 2012-07-12 モメンタ ファーマシューティカルズ インコーポレイテッド ＣＨＯ細胞由来の糖タンパク質産物におけるガラクトース−α−１，３−ガラクトース含有Ｎ−グリカン
CA2778158A1 (fr) * 2009-10-22 2011-04-28 Eiger Health Partners, Llc Compositions, procedes de traitement et de diagnostic de troubles lies a l'auto-immunite et procede de fabrication de telles compositions
US20110136682A1 (en) 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
WO2014018747A2 (fr) * 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoprotéines ayant des propriétés anti-inflammatoires
EP2991666B1 (fr) * 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
ES2708759T3 (es) * 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
EP3058084A4 (fr) * 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
DK3099317T3 (en) * 2014-01-29 2021-08-23 Enzymatica Ab Cod trypsin for use in the treatment of microbial infections in a subject with immunodeficiency
WO2017172853A1 (fr) * 2016-03-30 2017-10-05 Ab Biosciences, Inc. Compositions d'immunoglobuline intraveineuse recombinante (rivig) et leurs procédés de production et d'utilisation
MX2019007411A (es) * 2016-12-21 2019-08-29 Hoffmann La Roche Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.

Also Published As

Publication number Publication date
KR20250160224A (ko) 2025-11-11
AU2026206167A1 (en) 2026-08-06
WO2020077298A1 (fr) 2020-04-16
CN113438953A (zh) 2021-09-24
WO2020077298A9 (fr) 2020-05-22
AU2019357842A1 (en) 2021-05-13
EP3863673A4 (fr) 2023-01-11
JP2022502466A (ja) 2022-01-11
US20250195643A1 (en) 2025-06-19
CA3115821A1 (fr) 2020-04-16
KR20210077706A (ko) 2021-06-25
EP4567428A2 (fr) 2025-06-11
IL282136A (en) 2021-05-31
JP2025186266A (ja) 2025-12-23
EP3863673A1 (fr) 2021-08-18
EP4567428A3 (fr) 2025-10-01
BR112021006852A2 (pt) 2021-08-17
US20210353752A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
EP3863673A4 (fr) Traitement avec des compositions d'igg hautement sialylées
IL281210A (en) Preparations for the treatment of the disease with conjugates that stimulate the immune system
EP3856173A4 (fr) Traitement d'hémopathie maligne avec des inhibiteurs de ménine
MA45192A (fr) Traitement d'association
IL281809A (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
EP3781214A4 (fr) Compositions et procédés de traitement de l'amyotrophie spinale
EP3820490A4 (fr) Compositions d'aav
EP3875542A4 (fr) Composition d'émulsion de silicone
EP3827837A4 (fr) Composition visant à prévenir et traiter des maladies liées au système immunitaire
IL268905B (en) Phage therapy
LT3979827T (lt) Maistinė kompozicija, apimanti 2‘-fukozillaktozę ir 3‘-galaktozillaktozę
EP3820980A4 (fr) Compositions d'esterquats
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3706558A4 (fr) Compositions et procédés d'aquaculture
EP3763327A4 (fr) Dispositif de traitement d'aorte
EP4085053A4 (fr) Traitement du cancer avec des inhibiteurs de cdk12/13
UA120999C2 (uk) Естери оксаборолу та їх використання
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3344071A4 (fr) Compositions combinées pour réguler des niveaux de glycémie, l'hépatoprotection, et pour la prévention et le traitement d'états médicaux associés
MA52738A (fr) Méthodes de traitement de l'arthrite psoriasique
EP3809062A4 (fr) Vanne d'arrêt
EP3769784A4 (fr) Composition de suppression de l'inflammation
EP3632430A4 (fr) Agent de prévention ou de traitement de l'ataxie spinocérébelleuse
EP3675846A4 (fr) Méthodes et compositions de traitement d'une infection et d'une inflammation avec du sélénocyanate